Zomedica reports record Q4 revenue $10.5M, full-year revenue $32.0M (+17% YoY)

Zomedica Corp.

Q4 revenue $10.5M (+33% YoY); full year $32.0M (+17%). Record 20th straight YoY increase.
Gross margin 68% for year; Q4 69% best quarter. Adjusted EBITDA loss improved to $17.1M from $20.2M.
Cash burn reduced to $18.1M for year, $1.1M in Q4; cash/securities $53.3M.
Consumable revenue grew 16% to $20.7M; Development Services segment contributed $3.1M.
Net loss $81.9M includes $55.8M non-cash impairment; operating expenses ex-impairment down 7%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zomedica Corp. reported the year ended December 31, 2025 results: revenue $32.0 million, net income $81.9 million.

Period: the year ended December 31, 2025
Revenue: $32.0 million
Net income: $81.9 million
Result: reported results

Exact text from the filing

(PRESS RELEASE) --- EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity Zomedica surpasses $10 million in quarterly revenue for the first time

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zomedica Corp. reported the fourth quarter ended December 31, 2025 results: revenue $10.5 million.

Period: the fourth quarter ended December 31, 2025
Revenue: $10.5 million
Result: reported results

Exact text from the filing

Revenue for the fourth quarter of 2025 grew 33% to $10.5 million

View on SEC.gov

Browse all earnings releases →

Zomedica Corp. filing history →

Source: SEC EDGAR

accession 0001654954-26-002304

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.